> Details

Pomponio, G.; Ferrarini, A.; Bonifazi, M.; Moretti, M.; Salvi, A.; Giacometti, A.; Tavio, M.; Titolo, G.; Morbidoni, L.; Frausini, G.; Onesta, M.; Amico, D.; Rocchi, M. L. B.; Menzo, S.; Zuccatosta, L.; Mei, F.; Menditto, V.; Svegliati, S.; Donati, A.; D'Errico, M. M.; Pavani, M.; Gabrielli, A.

Tocilizumab in COVID‐19 interstitial pneumonia

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Tocilizumab in COVID‐19 interstitial pneumonia
  • Contributor: Pomponio, G.; Ferrarini, A.; Bonifazi, M.; Moretti, M.; Salvi, A.; Giacometti, A.; Tavio, M.; Titolo, G.; Morbidoni, L.; Frausini, G.; Onesta, M.; Amico, D.; Rocchi, M. L. B.; Menzo, S.; Zuccatosta, L.; Mei, F.; Menditto, V.; Svegliati, S.; Donati, A.; D'Errico, M. M.; Pavani, M.; Gabrielli, A.
  • Published: Wiley, 2021
  • Published in: Journal of Internal Medicine, 289 (2021) 5, Seite 738-746
  • Language: English
  • DOI: 10.1111/joim.13231
  • ISSN: 0954-6820; 1365-2796
  • Origination:
  • Footnote:
  • Description: AbstractBackgroundPublished reports on tocilizumab in COVID‐19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues.MethodsThis open‐label trial, structured according to Simon's optimal design, aims to identify factors predicting which patients could benefit from anti‐IL6 strategies and to enhance the design of unequivocal and reliable future randomized trials. A total of 46 patients with COVID‐19 pneumonia needing of oxygen therapy to maintain SO2 > 93% and with recent worsening of lung function received a single infusion of tocilizumab. Clinical and biological markers were measured to test their predictive values. Primary end point was early and sustained clinical response.ResultsTwenty‐one patients fulfilled pre‐defined response criteria. Lower levels of IL‐6 at 24 h after tocilizumab infusion (P = 0.049) and higher baseline values of PaO2/FiO2 (P = 0.008) predicted a favourable response.ConclusionsObjective clinical response rate overcame the pre‐defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.
  • Access State: Open Access